Tranexamic Acid Integrated into PRF Produces Robust and Resilient Antihemorrhagic Biological Agent: a human cohort study

Abstract

Objectives

To investigate the incorporation of the anti-fibrinolytic agent, tranexamic-acid (TA), during platelet rich fibrin (PRF) formation to produce robust fibrin agent with pro-coagulation properties.

Study design

Blood from healthy volunteers was collected. Into three tubes TA was immediately added in 1ml, 0.4ml and 0.2ml volumes and the fourth tube was without additions. Following PRF preparation, the clots weighted in their raw (clot) and membrane forms. PRF physical properties were analyzed using a universal testing systems (Instron). Protein and TA levels in the PRFs were analyzed using bicinchoninic acid assay and ferric-chloride assay respectively.

Results

The addition of TA to the PRF led to a robust weight compared with sham control. PRFs weight was greater in females in in all tested groups. The addition of TA also led to greater resilience to tear, especially at 1ml TA addition to the blood. Furthermore, TA addition led to greater value of total protein within the PRF, and entrapment of TA in the PRF.

Conclusions

Addition of TA to PRF preparation leads to robust PRF, with greater protein levels and the amalgamation of TA into the PRF. Such agent may enhance the beneficial properties of PRF and attribute pro-coagulation properties to it.